Cluster Headache: Preventive Treatment
Preventive therapy is the backbone of cluster headache management. Every patient in an active cluster bout should be on a preventive medication. Verapamil is the established first-line agent, despite limited RCT data, based on decades of clinical experience and one pivotal trial. For episodic cluster, prevention is maintained through the expected bout duration plus 2-4 weeks, then tapered. For chronic cluster, long-term prevention is often needed. CGRP monoclonal antibodies are an emerging option with positive trial data, particularly galcanezumab.
Bottom Line
- Verapamil (240-960 mg/day): First-line. Level B. Requires ECG monitoring at each dose increase (PR prolongation risk). Slow titration over 2-3 weeks.
- Lithium (600-1200 mg/day): Second-line. Level B. Better evidence for chronic than episodic cluster. Requires serum levels + renal/thyroid monitoring.
- Galcanezumab 300 mg SC monthly: Only CGRP mAb with positive RCT for episodic cluster headache. Reduces weekly attack frequency by ~50% vs placebo.
- Melatonin 10 mg at bedtime: Level C. Low risk; reasonable adjunct. Addresses circadian dysregulation.
- Topiramate, valproate, gabapentin: Used as third-line in refractory cases; limited evidence
Verapamil
The most widely used preventive for cluster headache, with decades of clinical experience despite limited randomized data.
Evidence
- Leone et al. (2000): Only RCT — verapamil 360 mg/day vs placebo in episodic cluster. Significant reduction in attack frequency in weeks 1 and 2 (p<0.05). Small trial (n=30).
- AHS guidelines (2016): Level B recommendation based on this trial plus extensive clinical experience and expert consensus
- Open-label data suggest that higher doses (480-960 mg/day) are often needed, especially for chronic cluster
Dosing and Monitoring
Verapamil: Practical Prescribing
- Start: 80 mg TID (240 mg/day) — use immediate-release, not sustained-release (better evidence, more flexible dosing)
- Titrate: Increase by 80 mg every 10-14 days
- Target: 480-720 mg/day (some patients need up to 960 mg/day for chronic cluster)
- ECG required: At baseline AND at every dose increase. Monitor for PR prolongation (>200 ms is concerning; >240 ms or new heart block — do not increase further). Repeat ECG 10-14 days after each increase.
- Duration (episodic cluster): Maintain throughout the expected bout duration + 2-4 weeks, then taper by 80 mg every 1-2 weeks
- Duration (chronic cluster): Ongoing. Reassess periodically; some patients can taper to lower maintenance dose.
- Constipation is the most common side effect (very common at high doses). Manage proactively with stool softeners.
- Other side effects: Edema, hypotension, fatigue, gingival hyperplasia (at high doses), bradycardia
Verapamil Cardiac Monitoring
- Cluster headache patients are often prescribed doses of verapamil well above standard cardiac doses (cardiac dose is typically 120-360 mg/day)
- Heart block (first-degree, second-degree, or third-degree AV block) can occur at any dose but risk increases above 480 mg/day
- ECG at baseline and every dose increase is mandatory — this is the most important safety measure
- If PR interval exceeds 240 ms or new AV block develops, do not increase further and consider dose reduction or switch to alternative
- Avoid combining verapamil with beta-blockers (additive AV conduction delay)
Lithium
Evidence
- Bussone et al. (1990): RCT of lithium vs verapamil in chronic cluster — equivalent efficacy (~70% response rate in both groups)
- Steiner et al. (1997): Lithium vs placebo in episodic cluster — positive but small trial
- Best evidence is for chronic cluster headache. Can be combined with verapamil for refractory chronic cluster.
Dosing
| Parameter | Details |
|---|---|
| Starting dose | 300 mg BID |
| Target dose | 600-1200 mg/day (divided BID-TID) |
| Target serum level | 0.6-1.0 mEq/L (lower end of therapeutic range) |
| Monitoring | Serum lithium level 5 days after each dose change, then monthly during treatment. Baseline and periodic: renal function (Cr, eGFR), thyroid function (TSH), calcium. |
| Key side effects | Tremor, polyuria/polydipsia, hypothyroidism (10-20%), nausea, weight gain, cognitive dulling |
| Toxicity signs | Coarse tremor, ataxia, confusion, vomiting — check level immediately. Toxicity at >1.5 mEq/L. |
Lithium Interactions
- NSAIDs: Increase lithium levels (reduced renal clearance) — use with caution; monitor levels more frequently
- ACE inhibitors, ARBs, diuretics: Increase lithium levels
- Dehydration: Cluster patients should maintain adequate hydration to avoid lithium accumulation
- Do not combine with sumatriptan in a way that suggests serotonin syndrome risk — in practice, the combination is used but monitoring is prudent
CGRP Monoclonal Antibodies
Galcanezumab
The only CGRP mAb with positive RCT data in cluster headache.
- Goadsby et al. (N Engl J Med 2019): Randomized, double-blind, placebo-controlled trial of galcanezumab 300 mg SC monthly in episodic cluster headache (n=106)
- Results: Weekly attack frequency reduced by 8.7 (galcanezumab) vs 5.2 (placebo) at weeks 1-3 (p=0.04). The 50% responder rate was significantly higher with galcanezumab.
- FDA status: FDA-approved for episodic cluster headache (June 2019) — the first and only drug approved for this indication; also approved for migraine prevention (2018). Not approved for chronic cluster (Phase 3 chronic trial was negative).
- Dose: 300 mg SC monthly (higher than migraine dose of 120 mg)
Other CGRP Agents
- Fremanezumab: Negative Phase 3 trial in episodic cluster (did not meet primary endpoint)
- Erenumab: No completed RCTs for cluster headache. Case series suggest possible benefit; not enough evidence to recommend.
- Eptinezumab: No cluster headache trials
Other Preventive Options
| Agent | Dose | Evidence | Notes |
|---|---|---|---|
| Melatonin | 10 mg at bedtime | Level C. Leone (2004): positive small RCT. Addresses hypothalamic/circadian mechanism of cluster. | Very low risk. Reasonable add-on for all cluster patients. Best as adjunct, not monotherapy. |
| Topiramate | 100-200 mg/day | Level C. Open-label positive data. No RCTs for cluster. | Third-line option. Same side effect profile as in migraine (cognitive, weight loss, paresthesias). |
| Valproate | 500-1500 mg/day | Limited. El Amrani (2002): positive open-label. Negative RCT (underpowered). | Third-line. Monitoring (LFTs, CBC). Avoid in women of childbearing potential (teratogenicity). |
| Gabapentin | 800-3600 mg/day | Case series only. No RCTs. | Last-line option. Sedation. May be useful as add-on in refractory chronic cluster. |
| Baclofen | 15-30 mg/day | Very limited (case reports) | Rarely used. GABA-B agonist. Anecdotal benefit in some refractory patients. |
Refractory Chronic Cluster
Approach to Refractory Chronic Cluster Headache
- Maximize verapamil (up to 960 mg/day with ECG monitoring)
- Add lithium (combination with verapamil is commonly used in refractory chronic cluster)
- Add galcanezumab 300 mg SC monthly (off-label for chronic cluster — the Phase 3 chronic cluster trial was negative [Dodick 2020]; FDA approval is for episodic cluster only)
- Adjuncts: Melatonin 10 mg, topiramate, serial GON blocks
- Consider occipital nerve stimulation (ONS): Implanted neurostimulator. Multiple open-label studies and one sham-controlled trial show ~60% of chronic cluster patients achieve ≥50% reduction. Reserved for patients who have failed ≥3 adequate preventive trials.
- Consider SPG stimulation: Pulsante device (implanted at the sphenopalatine ganglion). Pathway CH-1 and CH-2 studies showed efficacy for acute and preventive treatment. Available in Europe; limited US availability.
- Deep brain stimulation (posterior hypothalamus): Experimental. Small case series show benefit in the most refractory patients. Risks include hemorrhage. Only at specialized centers.
Prevention Algorithm
| Line | Episodic Cluster | Chronic Cluster |
|---|---|---|
| First-line | Verapamil (+ steroid bridge or GON block) | Verapamil (high-dose, may need 720-960 mg) |
| Second-line | Lithium or galcanezumab 300 mg | Add lithium to verapamil (galcanezumab is not proven in chronic cluster — negative Phase 3 trial) |
| Third-line | Topiramate, melatonin adjunct | Topiramate, valproate, or combination of multiple agents |
| Refractory | Rare; consider combination therapy | Occipital nerve stimulation, SPG stimulation, clinical trials |
References
- Leone M, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology. 2000;54(6):1382-1385.
- Bussone G, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30(7):411-417.
- Goadsby PJ, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132-141.
- Leone M, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia. 1996;16(7):494-496.
- Robbins MS, et al. Treatment of cluster headache: the American Headache Society evidence-based guidelines. Headache. 2016;56(7):1093-1106.
- May A, et al. Cluster headache. Nat Rev Dis Primers. 2018;4:18006.